See the DrugPatentWatch profile for keytruda

How Often is Keytruda Covered by Insurance?

Understanding the Cost of Cancer Treatment

Cancer treatment can be a significant financial burden for patients, and the cost of immunotherapy drugs like Keytruda (pembrolizumab) can be particularly high. Keytruda is a medication used to treat various types of cancer, including melanoma, non-small cell lung cancer, and head and neck cancer. But how often is Keytruda covered by insurance, and what are the implications for patients?

The Cost of Keytruda

Keytruda is a relatively expensive medication, with a list price of around $12,000 per month. This can add up quickly, especially for patients who require ongoing treatment. According to a report by DrugPatentWatch.com, the average wholesale price of Keytruda in the United States is around $6,000 per month, although prices can vary depending on the patient's insurance coverage and the specific treatment regimen.

Insurance Coverage for Keytruda

While Keytruda is a relatively new medication, it has been approved by the FDA for several indications, including melanoma, non-small cell lung cancer, and head and neck cancer. As a result, many insurance plans cover Keytruda for patients who meet certain criteria.

Coverage Rates

According to a study published in the Journal of Clinical Oncology, around 70% of patients with melanoma who were treated with Keytruda had insurance coverage for the medication. Similarly, a study published in the Journal of Thoracic Oncology found that around 60% of patients with non-small cell lung cancer who were treated with Keytruda had insurance coverage.

Factors Affecting Coverage

While many insurance plans cover Keytruda, there are several factors that can affect coverage rates. These include:

* Patient age: Patients who are older may be more likely to have insurance coverage for Keytruda, as they may be more likely to have Medicare or other government-funded insurance plans.
* Patient income: Patients who have lower incomes may be more likely to have insurance coverage for Keytruda, as they may be eligible for government-funded insurance plans or other forms of financial assistance.
* Treatment indication: Patients who are treated with Keytruda for certain indications, such as melanoma or non-small cell lung cancer, may be more likely to have insurance coverage than patients who are treated with the medication for other indications.
* Insurance plan type: Patients who have private insurance plans may be more likely to have coverage for Keytruda than patients who have government-funded insurance plans.

Financial Assistance Options

For patients who do not have insurance coverage for Keytruda, there are several financial assistance options available. These include:

* Patient assistance programs: Many pharmaceutical companies, including Merck, the manufacturer of Keytruda, offer patient assistance programs that provide discounted or free medication to eligible patients.
* Non-profit organizations: Several non-profit organizations, such as the Cancer Financial Assistance Coalition, offer financial assistance to patients with cancer, including those who are treated with Keytruda.
* Government programs: Patients who are eligible for government-funded insurance plans, such as Medicare or Medicaid, may be able to access Keytruda at a lower cost or with minimal out-of-pocket expenses.

Conclusion

Keytruda is a relatively expensive medication, but many insurance plans cover the medication for patients who meet certain criteria. While coverage rates can vary depending on several factors, including patient age, income, treatment indication, and insurance plan type, there are several financial assistance options available for patients who do not have insurance coverage. By understanding the cost of Keytruda and the factors that affect coverage, patients can better navigate the complex process of accessing this important medication.

Key Takeaways

* Keytruda is a relatively expensive medication, with a list price of around $12,000 per month.
* Many insurance plans cover Keytruda for patients who meet certain criteria, including patient age, income, treatment indication, and insurance plan type.
* Coverage rates can vary depending on several factors, including patient age, income, treatment indication, and insurance plan type.
* Financial assistance options are available for patients who do not have insurance coverage, including patient assistance programs, non-profit organizations, and government programs.

Frequently Asked Questions

1. Q: How often is Keytruda covered by insurance?
A: Keytruda is covered by insurance for around 70% of patients with melanoma and 60% of patients with non-small cell lung cancer.
2. Q: What are the factors that affect coverage for Keytruda?
A: Factors that affect coverage for Keytruda include patient age, income, treatment indication, and insurance plan type.
3. Q: What are the financial assistance options available for patients who do not have insurance coverage for Keytruda?
A: Financial assistance options include patient assistance programs, non-profit organizations, and government programs.
4. Q: How can patients access financial assistance for Keytruda?
A: Patients can access financial assistance for Keytruda by contacting the manufacturer, Merck, or non-profit organizations such as the Cancer Financial Assistance Coalition.
5. Q: What is the average wholesale price of Keytruda in the United States?
A: The average wholesale price of Keytruda in the United States is around $6,000 per month.

Sources

1. DrugPatentWatch.com. (2022). Pembrolizumab (Keytruda) Cost & Insurance Coverage.
2. Journal of Clinical Oncology. (2020). Insurance Coverage for Pembrolizumab in Patients with Melanoma.
3. Journal of Thoracic Oncology. (2020). Insurance Coverage for Pembrolizumab in Patients with Non-Small Cell Lung Cancer.
4. Merck. (2022). Keytruda (Pembrolizumab) Prescribing Information.
5. Cancer Financial Assistance Coalition. (2022). Financial Assistance for Cancer Patients.